The Experts below are selected from a list of 4497 Experts worldwide ranked by ideXlab platform
Seonyang Park - One of the best experts on this subject based on the ideXlab platform.
-
topical recombinant human epidermal growth factor for Oral mucositis induced by intensive chemotherapy with hematopoietic stem cell transplantation final analysis of a randomized double blind placebo controlled phase 2 trial
PLOS ONE, 2017Co-Authors: Ji Won Kim, Myeong Gyu Kim, Hyun Jung Lee, Youngil Koh, Ji Hyun Kwon, Inho Kim, Seonyang ParkAbstract:The aim of this study was to evaluate the efficacy and safety of recombinant human epidermal growth factor (rhEGF) Oral Spray for Oral mucositis (OM) induced by intensive chemotherapy with hematopoietic stem cell transplantation. In this phase 2 study, patients were randomized to either rhEGF (50 microg/mL) or placebo in a 1:1 ratio. The primary endpoint was incidence of National Cancer Institute (NCI) grade ≥2 OM. A total of 138 patients were enrolled in this study. In the intention-to-treat analysis, rhEGF did not reduce the incidence of NCI grade ≥2 OM (p = 0.717) nor reduce its duration (p = 0.725). Secondary endpoints including the day of onset and duration of NCI grade ≥2 OM, the incidence of NCI grade ≥3 OM and its duration, and patient-reported quality of life were also similar between the two groups. In the per-protocol analysis, however, the duration of opioid analgesic use was shorter in the rhEGF group (p = 0.036), and recipients in the rhEGF group required a lower cumulative dose of opioid analgesics than those in the placebo group (p = 0.046), among patients with NCI grade ≥2 OM. Adverse events were mild and transient. This study found no evidence to suggest that rhEGF Oral Spray reduces the incidence of OM. However, further studies are needed to investigate the effect of rhEGF on OM-induced pain reduction after intensive chemotherapy.
Mikhail V Kopp - One of the best experts on this subject based on the ideXlab platform.
-
phase ii randomized double blind placebo controlled study of recombinant human intestinal trefoil factor Oral Spray for prevention of Oral mucositis in patients with colorectal cancer who are receiving fluorouracil based chemotherapy
Journal of Clinical Oncology, 2009Co-Authors: Douglas E Peterson, Nicholas P Barker, Lilia I Akhmadullina, Irina Rodionova, Nailya Z Sherman, Irina Davidenko, Galina N Rakovskaya, Eugeny A Gotovkin, Sergey A Shinkarev, Mikhail V KoppAbstract:Purpose This study evaluated the safety and efficacy of recombinant human intestinal trefoil factor (rhITF) administered as topical Oral Spray for prevention and treatment of chemotherapy-induced Oral mucositis (OM). Patients and Methods Ninety-nine patients with colorectal cancer who had moderate to severe OM (WHO grade ≥ 2) in the first cycle of chemotherapy were randomly assigned to receive either placebo, rhITF 10 mg/mL (ie, low dose), or rhITF 80 mg/mL (ie, high dose) by Oral Spray (300 μL, eight times each day) for 14 consecutive days in the second chemotherapy cycle. Patients were assessed on days 1, 3, 5, 7, 10, 12, 14, and 21 (± 2 days for the last assessment) for safety and for OM incidence and severity. Results Treatment of patients at high risk for developing OM with low- or high-dose rhITF significantly reduced the amount of incidence (75% to 81%; low-dose rhITF P < .001; high-dose rhITF P = .002). Frequencies of WHO grade ≥ 2 OM in the placebo, low-dose rhITF, and high-dose rhITF groups were...
Pamela J Magee - One of the best experts on this subject based on the ideXlab platform.
-
vitamin d3 supplementation using an Oral Spray solution resolves deficiency but has no effect on vo2 max in gaelic footballers results from a randomised double blind placebo controlled trial
European Journal of Nutrition, 2017Co-Authors: Joshua J Todd, Emeir M Mcsorley, Kirsty L Pourshahidi, Sharon M Madigan, Eamon Laird, Martin Healy, Pamela J MageeAbstract:Purpose Vitamin D inadequacy is a global health concern in athletes as well as the general population. Whilst the role of vitamin D in skeletal health is well defined, there remains uncertainty over whether vitamin D supplementation has an added benefit beyond bone health.
Youngil Koh - One of the best experts on this subject based on the ideXlab platform.
-
topical recombinant human epidermal growth factor for Oral mucositis induced by intensive chemotherapy with hematopoietic stem cell transplantation final analysis of a randomized double blind placebo controlled phase 2 trial
PLOS ONE, 2017Co-Authors: Ji Won Kim, Myeong Gyu Kim, Hyun Jung Lee, Youngil Koh, Ji Hyun Kwon, Inho Kim, Seonyang ParkAbstract:The aim of this study was to evaluate the efficacy and safety of recombinant human epidermal growth factor (rhEGF) Oral Spray for Oral mucositis (OM) induced by intensive chemotherapy with hematopoietic stem cell transplantation. In this phase 2 study, patients were randomized to either rhEGF (50 microg/mL) or placebo in a 1:1 ratio. The primary endpoint was incidence of National Cancer Institute (NCI) grade ≥2 OM. A total of 138 patients were enrolled in this study. In the intention-to-treat analysis, rhEGF did not reduce the incidence of NCI grade ≥2 OM (p = 0.717) nor reduce its duration (p = 0.725). Secondary endpoints including the day of onset and duration of NCI grade ≥2 OM, the incidence of NCI grade ≥3 OM and its duration, and patient-reported quality of life were also similar between the two groups. In the per-protocol analysis, however, the duration of opioid analgesic use was shorter in the rhEGF group (p = 0.036), and recipients in the rhEGF group required a lower cumulative dose of opioid analgesics than those in the placebo group (p = 0.046), among patients with NCI grade ≥2 OM. Adverse events were mild and transient. This study found no evidence to suggest that rhEGF Oral Spray reduces the incidence of OM. However, further studies are needed to investigate the effect of rhEGF on OM-induced pain reduction after intensive chemotherapy.
Inho Kim - One of the best experts on this subject based on the ideXlab platform.
-
topical recombinant human epidermal growth factor for Oral mucositis induced by intensive chemotherapy with hematopoietic stem cell transplantation final analysis of a randomized double blind placebo controlled phase 2 trial
PLOS ONE, 2017Co-Authors: Ji Won Kim, Myeong Gyu Kim, Hyun Jung Lee, Youngil Koh, Ji Hyun Kwon, Inho Kim, Seonyang ParkAbstract:The aim of this study was to evaluate the efficacy and safety of recombinant human epidermal growth factor (rhEGF) Oral Spray for Oral mucositis (OM) induced by intensive chemotherapy with hematopoietic stem cell transplantation. In this phase 2 study, patients were randomized to either rhEGF (50 microg/mL) or placebo in a 1:1 ratio. The primary endpoint was incidence of National Cancer Institute (NCI) grade ≥2 OM. A total of 138 patients were enrolled in this study. In the intention-to-treat analysis, rhEGF did not reduce the incidence of NCI grade ≥2 OM (p = 0.717) nor reduce its duration (p = 0.725). Secondary endpoints including the day of onset and duration of NCI grade ≥2 OM, the incidence of NCI grade ≥3 OM and its duration, and patient-reported quality of life were also similar between the two groups. In the per-protocol analysis, however, the duration of opioid analgesic use was shorter in the rhEGF group (p = 0.036), and recipients in the rhEGF group required a lower cumulative dose of opioid analgesics than those in the placebo group (p = 0.046), among patients with NCI grade ≥2 OM. Adverse events were mild and transient. This study found no evidence to suggest that rhEGF Oral Spray reduces the incidence of OM. However, further studies are needed to investigate the effect of rhEGF on OM-induced pain reduction after intensive chemotherapy.